Research and Factsheets
Research
2025
Capital Access Group - FDA extends use of XENOVIEW® to 6-year-olds
2 June 2025 (PDF - 412KB)

2025
Capital Access Group - FY24 results - sales growth guidance reiterated
8 May 2025 (PDF - 544KB)

2025
Capital Access Group - Investor update presentation confirms thesis
13 March 2025 (PDF - 262KB)

2025
Capital Access Group - FY24 update - Xenon MRI pharma research collaboration
10 March 2025 (PDF - 262KB)

2025
Capital Access Group - FY24 update - Even better than expected
27 February 2025 (PDF - 540KB)

Factsheets
2024
Company Summary
December 2024 (PDF - 1.2MB)

Latest News
-
Promotion & Sales Representative Agreement
24 June 2025 -
Result of AGM
09 June 2025 -
FDA expands XENOVIEW® indication to include children from six years of age
02 June 2025
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts